[Featured Stock] Gold Pacific Hits Upper Limit Day Before, Surges Two Days in a Row

Lee Nak-yeon, leader of the Democratic Party of Korea, is delivering a greeting at the international development trends and domestic policy forum on cell-based COVID-19 treatments held at the National Assembly on the 21st. Photo by Yoon Dong-joo doso7@

[Asia Economy Reporter Ji Yeon-jin] Gold Pacific, a developer of COVID-19 treatments, has been soaring for two consecutive days as of the 20th.

Gold Pacific is trading at 2,515 won, up 20.5% since the market opened this morning. The stock has been on the rise since the previous day amid expectations for domestic pharmaceutical companies' development of COVID-19 treatments. The company closed at the daily limit yesterday.

Gold Pacific's subsidiary, APRG, signed a consortium agreement last August with Genencell, Korea Pharma, Korea Institute of Pharmaceutical Research, and Kyung Hee University Industry-Academic Cooperation Foundation to jointly develop a COVID-19 treatment based on 'APRG64'.